Next Article in Journal
Correlation Analysis of Protein Expression of 10 HDAC/Sirtuin Isoenzymes with Sensitivities of 23 Anticancer Drugs in 17 Cancer Cell Lines and Potentiation of Drug Activity by Co-Treatment with HDAC Inhibitors
Previous Article in Journal
Pencil Beam Scanning (PBS) Intensity-Modulated Proton Therapy (IMPT) Chemoradiotherapy for Anal Canal Cancer—Single Institution Experience
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 1
10.3390/cancers14010186
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma

Cancers 2022, 14(1), 186; https://doi.org/10.3390/cancers14010186
by Ambreen Muhammed 1,†, Claudia Angela Maria Fulgenzi 1,2,†, Sirish Dharmapuri 3,†, Matthias Pinter 4, Lorenz Balcar 4, Bernhard Scheiner 4, Thomas U. Marron 3, Tomi Jun 3, Anwaar Saeed 5, Hannah Hildebrand 5, Mahvish Muzaffar 6, Musharraf Navaid 6, Abdul Rafeh Naqash 6, Anuhya Gampa 7, Umut Ozbek 8, Junk-Yi Lin 8, Ylenia Perone 1, Bruno Vincenzi 2, Marianna Silletta 2, Anjana Pillai 7, Yinghong Wang 9, Uqba Khan 10, Yi-Hsiang Huang 11, Dominik Bettinger 12, Yehia I. Abugabal 13, Ahmed Kaseb 13, Tiziana Pressiani 14, Nicola Personeni 14,15, Lorenza Rimassa 14,15, Naoshi Nishida 16, Luca Di Tommaso 17, Masatoshi Kudo 16, Arndt Vogel 18, Francesco A. Mauri 1, Alessio Cortellini 1, Rohini Sharma 1, Antonio D’Alessio 1,15, Celina Ang 3,‡ and David J. Pinato 1,*,‡add Show full author list remove Hide full author list
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Cancers 2022, 14(1), 186; https://doi.org/10.3390/cancers14010186
Submission received: 14 October 2021 / Revised: 23 November 2021 / Accepted: 13 December 2021 / Published: 31 December 2021

Round 1

Reviewer 1 Report

Manuscript Number: cancers-1441759

Comments to author::

Major:

  1. Have baseline data of type 2 DM, lipid profile, BMI and hypertension in those hepatocellular carcinoma patients.
  2. Could you try to evaluate relationship between baseline data of type 2 DM, lipid profile, BMI, and hypertension and inflammatory status?
  3. Had all HCC patients be treated with standard dose of immune checkpoint drugs.

 

 

Author Response

Please see the attachment 

Author Response File: Author Response.pdf

Reviewer 2 Report

The work by Muhammed et al. was focused on the evaluation of the systemic inflammatory response as a clinical outcome in patients with hepatocellular carcinoma undergoing immunotherapy. By conducting a retrospective study including 362 patients with HCC receiving immune checkpoint inhibitors (ICI), the authors observed that patients with NLR>5 displayed a shorter OS and a lower ORR and PFS. Furthermore, they observed that NLR is an independent prognostic factor for OS while PLR independently predicted OS and PFS. Overall, this work provides novel relevant findings in the field. The work was nicely conducted and the analysis are robust. Only small concerns should be addressed in order to increase the overall quality of this work.

 

1 – Are there any differences of the prognostic value of these parameters according HCC etiology?

2 – In the multivariate analysis, it is not clear if the authors also included BLCL stage. Are these parameters independent on tumor stage?

3 – What about the other prognostic factors mentioned in introduction? Do the authors confirm their prognostic value? Are the new ones better predictors of prognosis compared to, for instance, CD3 and CD8 cells?

 

Author Response

Please see the attachment 

Author Response File: Author Response.pdf

Back to TopTop